MIXED

CorestemChemon's ALS stem cell therapy missed its Phase 3 primary in the full population

Neuronata-R hit its CAFS endpoint only in slow-progressing patients, and South Korea kept the drug's conditional approval anyway while a U.S. filing plan hinges on the subgroup result.

The ALSUMMIT Phase 3 trial of Neuronata-R (lenzumestrocel) missed its primary CAFS endpoint in the full study population, but met it in a subgroup of slow progressors.

By AppliedXLJuly 19, 2026Trial NCT04745299

Executive Summary

A Phase 3 trial of a cell therapy for ALS missed its registered primary endpoint across the full study population, but a subgroup of slower-progressing patients met that same endpoint.
South Korea's drug regulator renewed the therapy's conditional approval based on the subgroup data rather than the overall trial result, keeping the product on the market there.
The sponsor is now building a U.S. regulatory strategy, including a planned FDA meeting and a future marketing application, around the same subgroup finding rather than the full trial population.
A primary analysis that fails and a subgroup that succeeds is not the same evidentiary strength as a trial that meets its endpoint outright, and how regulators and competitors read that distinction will shape what this readout is worth.

The result

ALSUMMIT (NCT04745299) tested Neuronata-R, an autologous bone marrow-derived mesenchymal stem cell therapy given by intrathecal injection, against the joint rank-based Combined Assessment of Function and Survival (CAFS), the trial's registered primary outcome measure. Across the full population, the therapy did not reach statistical significance on that measure. Within a subgroup of patients classified as slow progressors, Neuronata-R met the CAFS primary endpoint and a secondary endpoint, the ALS Functional Rating Scale-Revised (ALSFRS-R), alongside improvement in slow vital capacity and a reduction in neurofilament light chain (NfL), a marker of axonal injury increasingly used as a basis for ALS regulatory decisions. The trial enrolled 123 patients, matching its target, across sites in South Korea. NCT04745299+1

The regulatory result

South Korea's Ministry of Food and Drug Safety approved a product license modification for Neuronata-R in May 2026, updating its label to reflect the completed ALSUMMIT data and keeping the therapy's conditional approval, first granted in 2014, intact. The modification rests on the slow-progressor subgroup result rather than the full-population miss. CorestemChemon said it is now working to resume manufacturing, with full-scale production expected early next year, and framed the decision as preserving a cell-based option for the patients most likely to benefit. Neuronata-R

Reading the split result

A subgroup finding carved out after a primary miss carries less evidentiary weight than a prespecified endpoint met across an entire study population, because it was identified once the full analysis was already known. That is the shape of this result: the overall trial did not separate Neuronata-R from the comparison group, and the positive signal emerged only in a subset defined by disease progression rate. The company itself has flagged safety as consistent with the therapy's known profile, so the readout's uncertainty sits in efficacy interpretation, not tolerability. Neuronata-R

The regulatory path forward

CorestemChemon said it is pursuing a Type C meeting with the FDA, a mid-development discussion on trial design or data, with the goal of filing a Biologics License Application for U.S. approval next year. Neuronata-R holds Orphan Drug Designation from the FDA, granted in 2018, and from the European Medicines Agency, granted in 2019. Two ALS therapies already carry FDA approval in this indication: riluzole and edaravone are approved for ALS broadly, and Biogen's tofersen (marketed as Qalsody) is approved for ALS in patients with a SOD1 gene mutation, granted under accelerated approval based on NfL reduction rather than a confirmed survival or function benefit. That precedent bears directly on Neuronata-R's subgroup result, which also leans on an NfL reduction, the same biomarker basis tofersen used to reach the U.S. market. Neuronata-R

The competitive field

Cell therapy is one of several modalities being tested in ALS, with roughly two dozen cell-therapy trials run in the indication industry-wide. The nearest same-modality programs include Brainstorm Cell Therapeutics' debamestrocel, also a Phase 3 mesenchymal stem cell candidate for ALS, and earlier-stage progenitor-cell programs from Q Therapeutics and XellSmart Bio-Pharmaceutical. None of those programs has a resolved outcome on record to benchmark against. Outside cell therapy, Biogen's tofersen and AB Science's masitinib represent the field's other late-stage mechanisms in ALS, each targeting a different biological pathway than Neuronata-R's immunomodulatory and neurotrophic factor secretion approach. Neuronata-R

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.